Meeting
2023 ASCO Annual Meeting
Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy.
Authors
Farzad Haerizadeh
Bio4t2, San Diego, CA
Farzad Haerizadeh , Helena Jiang , Laurence Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2540)
DOI
10.1200/JCO.2023.41.16_suppl.2540
Abstract #
2540
Poster Bd #
382
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.
First Author: Ritu Singla
Poster
2016 ASCO Annual Meeting
Towards a safer CD19 CART therapy with reduced risk of cytokine release syndrome (CRS).
First Author: Lucas H. Horan
Poster
2024 ASCO Breakthrough
Hypoxia-responsive synthetic gene circuits to improve safety and potency of CAR T cell therapy for solid tumors.
First Author: Yannick Schreiber
Poster
2024 ASCO Genitourinary Cancers Symposium
Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.
First Author: Kevin Chang